Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ADMA NASDAQ:AKRO NASDAQ:ALLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.68-0.2%$23.31$13.40▼$26.65$3.66B0.752.17 million shs192,456 shsADMAADMA Biologics$15.43+1.2%$15.85$13.50▼$25.67$3.68B0.473.15 million shs464,077 shsAKROAkero Therapeutics$53.700.0%$47.89$21.34▼$58.40$4.30B-0.291.63 million shs84,885 shsALLOAllogene Therapeutics$1.21-0.4%$1.20$0.86▼$3.78$267.37M0.434.11 million shs480,493 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ADMAADMA Biologics+0.59%+4.74%-4.57%-15.32%-2.80%AKROAkero Therapeutics+0.21%+0.11%+12.29%+6.25%+87.37%ALLOAllogene Therapeutics0.00%-4.72%+3.42%-19.33%-56.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.68-0.2%$23.31$13.40▼$26.65$3.66B0.752.17 million shs192,456 shsADMAADMA Biologics$15.43+1.2%$15.85$13.50▼$25.67$3.68B0.473.15 million shs464,077 shsAKROAkero Therapeutics$53.700.0%$47.89$21.34▼$58.40$4.30B-0.291.63 million shs84,885 shsALLOAllogene Therapeutics$1.21-0.4%$1.20$0.86▼$3.78$267.37M0.434.11 million shs480,493 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ADMAADMA Biologics+0.59%+4.74%-4.57%-15.32%-2.80%AKROAkero Therapeutics+0.21%+0.11%+12.29%+6.25%+87.37%ALLOAllogene Therapeutics0.00%-4.72%+3.42%-19.33%-56.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.3335.29% UpsideADMAADMA Biologics 3.25Buy$27.6779.27% UpsideAKROAkero Therapeutics 2.31Hold$73.3836.65% UpsideALLOAllogene Therapeutics 2.54Moderate Buy$8.44600.78% UpsideCurrent Analyst Ratings BreakdownLatest ADMA, ACAD, AKRO, and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025ACADACADIA PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$33.0010/14/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold10/10/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight10/9/2025AKROAkero TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/9/2025AKROAkero TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $56.0010/9/2025AKROAkero TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$73.00 ➝ $54.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.82$0.71 per share30.35$4.40 per share4.93ADMAADMA Biologics$426.45M8.64$0.55 per share28.01$1.48 per share10.43AKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AALLOAllogene Therapeutics$20K13,368.27N/AN/A$2.01 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3316.3228.537.3921.80%14.69%9.41%11/5/2025 (Estimated)ADMAADMA Biologics$197.67M$0.8617.9422.37N/A44.06%41.01%28.47%11/6/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)ALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)Latest ADMA, ACAD, AKRO, and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025AKROAkero Therapeutics-$0.94N/AN/AN/AN/AN/A11/6/2025Q3 2025ADMAADMA Biologics$0.16N/AN/AN/A$131.20 millionN/A11/6/2025Q3 2025ALLOAllogene Therapeutics-$0.23N/AN/AN/AN/AN/A11/5/2025Q3 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$276.52 millionN/A8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83ADMAADMA Biologics0.215.332.78AKROAkero Therapeutics0.0212.6612.66ALLOAllogene TherapeuticsN/A8.928.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ADMAADMA Biologics75.68%AKROAkero TherapeuticsN/AALLOAllogene Therapeutics83.63%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ADMAADMA Biologics3.50%AKROAkero Therapeutics7.07%ALLOAllogene Therapeutics13.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableADMAADMA Biologics530238.63 million230.28 millionOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableADMA, ACAD, AKRO, and ALLO HeadlinesRecent News About These CompaniesGeoffrey Parker Sells 36,744 Shares of Allogene Therapeutics (NASDAQ:ALLO) StockOctober 24 at 5:49 AM | insidertrades.comAllogene licensor Cellectis faces patent lawsuit in the U.S.October 14, 2025 | msn.comAllogene Therapeutics' (ALLO) Underweight Rating Reiterated at JPMorgan Chase & Co.October 13, 2025 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Stock Rating Lowered by Wall Street ZenOctober 12, 2025 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Given "Underweight" Rating at JPMorgan Chase & Co.October 11, 2025 | marketbeat.comAllogene Therapeutics' (ALLO) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB)October 7, 2025 | theglobeandmail.comAllogene Therapeutics (NASDAQ:ALLO) Rating Increased to Hold at Wall Street ZenOctober 4, 2025 | marketbeat.comAllogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 TranscriptOctober 4, 2025 | seekingalpha.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 30, 2025 | marketbeat.comWhy Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?September 12, 2025 | zacks.comInvesting in Oncology: 3 Cancer Stocks With Promising PipelinesSeptember 8, 2025 | zacks.comDiffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsightAugust 27, 2025 | finance.yahoo.comAllogene Therapeutics Announces Participation in Upcoming Investor ConferenceAugust 27, 2025 | globenewswire.comGlobal CAR T-Cell Therapy Market Set to Reach USD 29 Billion by 2029 | MarketsandMarkets™August 27, 2025 | finance.yahoo.comAllogene Therapeutics management to meet with Piper SandlerAugust 25, 2025 | msn.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | msn.comAllogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory ChallengesAugust 15, 2025 | msn.comAllogene Therapeutics: Q2 Earnings SnapshotAugust 14, 2025 | timesunion.comTAllogene Therapeutics reports Q2 EPS (23c), consensus (27c)August 14, 2025 | msn.comAllogene Narrows Loss in Fiscal Q2August 14, 2025 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Why Vertical Aerospace Could Lead the eVTOL Market by 2028By Jeffrey Neal Johnson | September 30, 2025ADMA, ACAD, AKRO, and ALLO Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.68 -0.05 (-0.22%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.ADMA Biologics NASDAQ:ADMA$15.43 +0.18 (+1.20%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Akero Therapeutics NASDAQ:AKRO$53.70 -0.03 (-0.05%) As of 11:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Allogene Therapeutics NASDAQ:ALLO$1.20 -0.01 (-0.41%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
